Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
about
From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implicationsPCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabLipids, blood pressure and kidney update 2015LDL cholesterol, statins and PCSK 9 inhibitorsProfile of evolocumab and its potential in the treatment of hyperlipidemiaDevelopment of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disordersThe year in cardiology 2015: preventionNew Era of Lipid-Lowering DrugsPCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic eraRetargeting the management of hypercholesterolemia - focus on evolocumabPCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the futurePCSK9 Inhibition With Monoclonal Antibodies: Modern Management of HypercholesterolemiaPCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk.PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers.Lipoprotein (a), an independent cardiovascular risk markerPCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Familial hypercholesterolemia: developments in diagnosis and treatmentLiving the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).PCSK9 antibodies for the treatment of hypercholesterolemiaIdentification of protein disulfide isomerase 1 as a key isomerase for disulfide bond formation in apolipoprotein B100.Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trialsIn silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.New Approaches in Detection and Treatment of Familial HypercholesterolemiaPCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.HDL subfractions and very early CAD: novel findings from untreated patients in a Chinese cohort.Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy.Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.Investigational therapies for the treatment of atherosclerosis.Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.PCSK9 inhibition: current concepts and lessons from human genetics.Shared genetic aetiology of coronary artery disease and atherosclerotic stroke - 2015.Pharmacokinetics, Pharmacodynamics of Bococizumab, a monoclonal antibody to PCSK9, After Single Subcutaneous Injection at 3 Sites [NCT 02043301].Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.Calorically restricted diets decrease PCSK9 in overweight adolescents.
P2860
Q26741078-4811C2E2-7F5F-4BF0-844F-221550333E32Q26747776-27DE50B3-F4C7-48CB-9C10-3A0ED96875D5Q26771550-46071E6A-EE78-4A3E-8378-6CB2C4C2130BQ26782522-257DB57E-5293-47BD-B803-99A254E0978EQ27004235-714C46ED-0247-40FD-8914-38BD5A93E557Q28070296-295A3815-F0E1-4515-A514-7ACE207900FFQ28072221-9FB7BD04-0A2A-4B31-8C5A-2FEBDEA819A9Q28072298-6EE1ACE6-1AAC-43E2-B76E-6111CEA6E266Q28073656-29B4869B-C10D-49F8-AD45-A460FC4A3C76Q28077289-7FCBE0C0-E4F4-428D-8D52-E4757B69968EQ28083595-3AC564D0-2217-44E2-AB2B-B6384563F660Q28275648-44C8D839-F65F-4A1E-AC58-71CDFFB3E3F2Q30234612-88305CB7-94F3-46D7-9C13-55AC6A175584Q30833167-ADAFE5A3-D103-47A2-B2F4-A02108F46E75Q31053398-1ACE131B-03F0-4113-AACF-45A6D2CCA514Q33625574-3018357C-D449-42D8-BACC-8DC02255BA32Q33801207-52CF8B1E-6478-4C2E-9031-55ED380D6173Q33904455-DECB736B-D046-4363-BCB9-890E07DA3B0BQ34106665-965D7C44-942D-4D91-9D80-B9072E77E557Q34430377-5AC856AC-99B0-453B-90D1-98F5F55F3CD0Q34458693-63A2CBBD-8E43-4D60-8436-31AA5897F241Q34774969-FB418268-4ED4-4AAF-A490-8535985DBE97Q35077000-7FD9F3D6-CB35-4CAA-BBCE-1C4E3FFF92BFQ35671077-4E5D7C0E-D242-4B39-868D-EDE942650A51Q35740919-1840BD91-650B-442C-A3E5-73DF7663B811Q36177473-C198B439-95E0-4AA5-8A7A-6C96046E70C4Q36930207-45439C66-8892-4188-8BB8-AE4EC323DD72Q37034257-09A6FC27-077A-4444-9345-16C97BC623CCQ37151344-DBA7F0BC-5C5C-473D-9567-18187DDDFC94Q37688760-29154675-7836-4D0D-95C1-3E7889EC6CDBQ37700671-9ED9DCC5-EF53-4E8F-B099-67EF1BA75631Q38198739-544B1A15-BFEB-450E-8098-7B339AA061B9Q38214386-6B123E14-0332-41F4-B216-E03BEC80CBABQ38221015-FE807909-0A0E-4982-B5FA-505277DD6694Q38285812-64FE3544-13F0-4608-A81A-55D63D2A3B6BQ38338236-EC8BD8A1-F895-4578-AC8E-C39633CC4AC1Q38359111-751231EE-E25E-4FC1-92DE-7FB4553690F7Q38375213-0614278E-16BF-4348-A5C9-267EF558BED9Q38379459-BECFC5CB-36BB-4391-A82D-6AC9FCBCCB9EQ38380440-02A75E5B-BCFD-4AFB-A42C-97740979581B
P2860
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Efficacy and safety of longer- ...... DL-C (OSLER) randomized trial.
@en
type
label
Efficacy and safety of longer- ...... DL-C (OSLER) randomized trial.
@en
prefLabel
Efficacy and safety of longer- ...... DL-C (OSLER) randomized trial.
@en
P2093
P1433
P1476
Efficacy and safety of longer- ...... DL-C (OSLER) randomized trial.
@en
P2093
David Sullivan
Fernando Civeira
Frederick J Raal
Gisle Langslet
Marc S Sabatine
Michael Bolognese
Michael J Koren
OSLER Investigators
Patric Nelson
Ransi Somaratne
P304
P356
10.1161/CIRCULATIONAHA.113.007012
P407
P577
2013-11-19T00:00:00Z